Загрузка...

Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report

RATIONALE. Neo-adjuvant systemic therapy includes endocrine therapy and chemotherapy, which is widely used. Luminal breast cancer is resistant to chemotherapy and is more likely to not respond to chemotherapy before surgery. Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor. Palbociclib wit...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Medicine (Baltimore)
Главные авторы: Jung, Sung Ui, Jung, Minjung, Choi, Jin Hyuk, Jeon, Chang Wan
Формат: Artigo
Язык:Inglês
Опубликовано: Lippincott Williams & Wilkins 2021
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8036054/
https://ncbi.nlm.nih.gov/pubmed/33832078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000025175
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!